Clinical significance of SQSTM1/P62 and nuclear factor-κB expression in pancreatic carcinoma

Table 1 Relationships among phosph-P65 expression, P62 expression, and clinicopathological features in pancreatic carcinomas (n = 40)

Clinicopathological feature	n	Phosph-P65			P value1	P62			P value1
		Positive		Negative		Positive		Negative
Gender	40	35		5	1.000	37		3	0.141
Male	24	21		3		21		3
Female	16	14		2		16		0
Age (yr)					0.329				0.806
< 60	24	22		2		22		2
≥ 60	16	13		3		15		1
Pathology type					0.002				0.746
Duct adenocarcinoma	29	27		2		26		3
Adenocarcinoma	9	8		1		9		0
Squamous cell carcinoma	1	0		1		1		0
Acinic cell carcinoma	1	0		1		1		0
T stage					0.885				0.001
T0	0	0		0		0		0
T1	1	1		0		0		1
T2	10	9		1		10		0
T3	29	25		4		27		2
T4	0	0		0		0		0
N stage					0.496				0.608
N0	37	32		5		34		3
N1	3	3		0		3		0
N2	0	0		0		0		0
N3	0	0		0		0		0
M stage					0.702				0.773
M0	39	34		5		36		3
M1	1	1		0		1		0
TNM stage					0.934				0.939
I	11	10		1		10		1
II	28	25		3		26		2
III	0	0		0		0		0
IV	1	1		0		1		0

¹Pearson χ². TNM: Tumor-node-metastasis.